Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 15, 2025 10:00 ET | Source: AscellaHealth, LLC

AscellaHealth’s Patient-Focused Approach is Best-in-Class Model for Distribution of Rare Disease Therapies

AscellaHealth’s Patient-Focused Approach is Best-in-Class Model for Distribution of Rare Disease Therapies
November 22, 2021 07:00 ET | Source: BioCryst Pharmaceuticals, Inc.

BioCryst Adds $350 Million in New Financing with Royalty Pharma and OMERS Capital Markets

—Provides funding for BCX9930/oral Factor D program across multiple indications— —Agreements supported by strength of ORLADEYO® (berotralstat) launch and confidence in future opportunity— NEW YORK,...
May 06, 2020 07:00 ET | Source: BioCryst Pharmaceuticals, Inc.

BioCryst Reports First Quarter 2020 Financial Results and Upcoming Key Milestones

—Berotralstat approval/launch timelines in U.S., Japan, EU remain on track— —Early clinical data supports BCX9930 as oral monotherapy for complement-mediated diseases— —Patient dosing underway in...
October 28, 2019 06:59 ET | Source: BioCryst Pharmaceuticals, Inc.

BioCryst Reports Data From Phase 1 Trial of BCX9930 and Announces Plans to Advance Program Into Proof of Concept Study in PNH Patients

—Phase 1 data showed rapid, sustained and >95% inhibition of alternative pathway of complement system with 100 mg of oral BCX9930 BID— —BCX9930 safe and generally well tolerated— —Part 1 SAD and...
June 27, 2019 16:15 ET | Source: BioCryst Pharmaceuticals, Inc.

Biocryst Begins Enrollment of Phase 1 Trial of BCX9930, an Oral Factor D Inhibitor for Complement-Mediated Diseases

—Data expected in Q4 2019— —BCX9930 showed high potency, specificity, suppression of hemolysis and wide safety margin in preclinical studies— RESEARCH TRIANGLE PARK, N.C., June 27, 2019 (GLOBE...
November 20, 2018 07:00 ET | Source: BioCryst Pharmaceuticals, Inc.

BioCryst Appoints Rare Disease Expert Theresa Heggie to Board of Directors

RESEARCH TRIANGLE PARK, N.C., Nov. 20, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company has appointed Theresa Heggie to its Board of Directors. ...
November 06, 2018 07:00 ET | Source: BioCryst Pharmaceuticals, Inc.

BioCryst Reports Third Quarter 2018 Financial Results

APeX-2 study enrollment completed, results on-track for Q2 2019 RESEARCH TRIANGLE PARK, N.C., Nov. 06, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced...
November 05, 2018 07:00 ET | Source: BioCryst Pharmaceuticals, Inc.

BioCryst to Present Abstracts at Annual Scientific Meeting of American College of Allergy, Asthma & Immunology

RESEARCH TRIANGLE PARK, N.C., Nov. 05, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present three abstracts at the upcoming Annual...